Clinical trials
Observational Alzheimer Disease trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Recruiting | 10 |
| Unknown status | 5 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novoic Limited | 4 |
| Imperial College London | 2 |
| University of Aberdeen | 2 |
| University of Edinburgh | 2 |
| Alnylam Pharmaceuticals | 1 |
| AstraZeneca | 1 |
| Brain Health Scotland Life Sciences Ltd | 1 |
| Eisai Limited | 1 |
| GAP Innovations, PBC | 1 |
| Indiana University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alzheimer Disease | 35 |
| Cognitive Dysfunction | 14 |
| Dementia | 14 |
| Dementia, Vascular | 4 |
| Cardiovascular Diseases | 2 |
| Disease | 2 |
| Lewy Body Disease | 2 |
| Memory Disorders | 2 |
| Osteoporosis | 2 |
| Pick Disease of the Brain | 2 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.